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Abstract
Small molecule vascular endothelial growth factor
(VEGF) receptor tyrosinase kinase inhibitors (VEGFR-
TKIs) show great promise in inducing antiangiogenic
responses in tumors. We investigated whether anti-
angiogenic tumor responses induced by an experi-
mental VEGFR-TKI (AG013925; Pfizer Global Research
and Development) could be reported by magnetic
resonance imaging (MRI) during the initial phase of
treatment. We used MRI and superparamagnetic nano-
particles for measuring relative vascular volume
fraction (rVVF) in a drug-resistant colon carcinoma
model. Athymic mice harboring MV522 xenografts
were treated with VEGFR-TKI (25 mg/kg, p.o., with a
12-hour interval in between treatments) and were
imaged after three consecutive treatments. Relative
tumor blood volume fractions were calculated using
#R2* maps that were scaled by the known VVF value
of an in-plane skeletal muscle (1.9%). There was a
pronounced and statistically significant (P < .001)
decrease of tumor rVVF in treated animals (0.95 ±
0.24%; mean ± SEM, n = 66 slices, eight mice) compared
to mice that received a placebo (2.91 ± 0.24%; mean ±
SEM, n = 66 slices, nine mice). Tumor histology con-
firmed a three-fold decrease of vascular density and a
concomitant increase of apoptotic cell index. Hence, we
demonstrated that: 1) the VEGFR-TKI resulted in anti-
angiogenic effects that were manifested by a decrease
or rVVF; and 2) iron oxide nanoparticles and steady-
state MRI enable an early detection of tumor response to
antiangiogenic therapies.
Neoplasia (2005) 7, 847–853
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Introduction
Tumor cells and/or tumor-recruited inflammatory and stro-
mal cells secrete chemokines and growth factors that
induce the proliferation of microvascular endothelial cells.
Vascular endothelial growth factor (VEGF) is one of the
multifunctional cytokines that bind to extracellular domains
of at least three different receptor kinases (VEGF receptor
[VEGFR]; VEGFR1–VEGFR3) and neuropilins involved in anti-
apoptotic signaling, mitosis, and cell taxis. Thus, VEGF is
an established target of antiangiogenic interventions [1]. In
recent years, both receptor-blocking antibodies as well as
small molecule inhibitors of receptor kinases have been de-
veloped as potential antiangiogenic drugs subject to many
clinical trials [1,2]. These molecules are capable of attenuat-
ing VEGFR-mediated signaling, thereby causing strong anti-
proliferative and antiangiogenic effects. These effects are
caused not only by the attenuation of endothelial mitogenic sig-
naling but also by the disruption of VEGF autocrine loop in
cancer cells [3–5].
Several experimental VEGFR2 kinase (KDR) inhibitors
have been tested in cancer models (e.g., SU5416 and SU6668
showed potent antiangiogenic responses resulting in a sig-
nificant reduction of tumor vascular density, changes in ves-
sel diameter, higher red blood cell velocity, and blood flow
in remnant tumor vessels when compared with the control
tumors) [6,7]. Consequently noted were abrogation of metas-
tasis, microvessel formation, cell proliferation, and apoptosis
[8]. Another experimental drug (SU11248) selectively inhibited
both VEGFR2 and PDGF receptor beta phosphorylation and
thereby caused the reduction of VEGF-mediated permeability of
blood vessels [9]. Similar findings of reduced microvascular
density, as well as blood flow changes, have been reported in
renal carcinoma models after treatment with the PTK787/ZK
222584 inhibitor of VEGFR tyrosine kinase [10,11]. Other
Abbreviations: VEGFR-TKI, VEGF receptor tyrosinase kinase inhibitor; rVVF, relative
vascular volume fraction
Address all correspondence to: Dr. Alexei Bogdanov, Jr., Department of Radiology, University
of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655.
E-mail: alexei.bogdanov@umassmed.edu
1This work has been supported in part by National Institutes of Health (NIH) grants
(1P50CA86355-01 (Project 2) and 5RO1 CA74424-01). W.R. received support from the
German National Academy Foundation (Studienstiftung). D.T. was supported by the NIH
Research Supplement for Underrepresented Minorities.
Received 18 January 2005; Revised 24 May 2005; Accepted 25 May 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05139
Neoplasia . Vol. 7, No. 9, September 2005, pp. 847 –853 847
www.neoplasia.com
RESEARCH ARTICLE
small molecule angiogenesis inhibitors (CGP 41251 [12]
and PKC412 [13]) showed a reduction of neovessel for-
mation in vivo. Another experimental VEGFR inhibitor,
AG013736 (Pfizer Global Research and Development, San
Diego, CA), has been effective in causing endothelial cell
regression in experimental tumors with a 70% decrease in
vascular density [14].
Furthermore, antiangiogenic drug research and devel-
opment prompted the validation of imaging techniques
designed for detecting and quantitating physiologic and mo-
lecular markers of angiogenesis (reviewed in Refs. [15,16]).
The strength of the imaging approach is in the ability to per-
form survival experiments in intact animals. The above imaging
detects changes in vascular endothelial marker expression
and physiologic parameters before the changes in tumor
volume become apparent.
Magnetic resonance imaging (MRI) combines excellent
anatomic resolution and sensitivity to blood volume and
flow changes caused by antiangiogenic treatments. For ex-
ample, a combination of dynamic contrast-enhanced MRI
with kinetic modeling has shown a potential for the detection
of drug-induced changes in tumor microvessels (reviewed
in Refs. [15,17]). For assessing changes in tumor blood
volume, two essentially different MRI approaches were be
used: 1) intravascular T1 agents (i.e., predominantly affect-
ing longitudinal relaxation of proton magnetization) enable
the quantification of relative as well as absolute blood
volume fractions [18,19]; 2) T2 agents (a bolus of paramag-
netic chelates [20,21] or an injection of superparamagnetic
nanoparticles [11,22–24]) affect the spin–spin relaxation
of water proton magnetization and enable relative blood
volume change assessment by dephased proton population.
In the current study, we used a 1.5-T clinical MR scan-
ner and steady-state imaging assisted by the injection of
nanoparticles for detecting changes in tumor vascular blood
volume induced by antiangiogenic therapy. We were specifi-
cally interested in determining whether iron oxide–enhanced
MRI could assess blood volume changes early after initiat-
ing the treatment of MV522 human drug-resistant carcinoma
xenografts with an experimental VEGFR2 kinase inhibitor.
Materials and Methods
Cell Culture
Human MV522 carcinoma cells (Pfizer Global Research
and Development) were grown in 15% fetal calf serum and
RPMI 1640 (Cellgro; Mediatech, Washington, DC).
Fluorescent Probes
Antidigoxigenin F(abV)2 fragment (Roche Diagnostics,
Indianapol is IN) was labeled with Cy3-mono-N -
hydroxysuccinimide ester (Amersham Biosciences, Piscata-
way, NJ) [25]. Tomato lectin was labeled using Alexa Fluor
488 N-hydroxysuccinimide ester (Molecular Probes, Inc.,
Eugene, OR). Fluorescent conjugates were purified using
Biospin P30 minicolumns (Bio-Rad, Hercules, CA).
Tumor Model
All animal experiments were approved and carried out
according to the MGH Animal Care and Use Committee.
Female nu/nu mice (25 g) were used for ectopic carci-
noma xenografting (n = 18 total). Two million MV522 cells
were injected in 100 ml of serum-free cell culture medium
subcutaneously in the bilateral lower flanks of mice. Approx-
imately 14 days after the implantation of cells, the animals
with tumors of an average size of approximately 5 mm in
diameter were divided into two groups (treatment and con-
trol) that underwent MRI at 1.5 T (see below). Control
animals received three doses of 0.5% carboxymethyl cel-
lulose (CMC) placebo (group 1, n = 8), whereas treated
animals received three doses of AG013925, 25 mg/kg, p.o.,
bid, in 0.5% CMC within 36 hours (group 2, n = 9; time delay
between dosing, 12 hours). One animal was excluded from
the study based on lack of tumor growth. Following treat-
ment, three radii of the tumors were measured using calipers
and the volumes were calculated as VT = 4/3pABC, where
A, B, and C are radii.
MRI of Mice
Animals were anesthetized using an intraperitoneal in-
jection of ketamine (80 mg/kg) and xylazine (12 mg/kg).
Custom-made 30-G needle catheters were inserted into
the tail vein and attached to a microheparin/saline flush unit.
Anesthetized mice were placed prone with tumors located
in the center of a custom-built transmit–receive parallel
wound solenoid coil (30 mm diameter  50 mm length; Nova
Medical, Wilmington, MA) preheated to 37jC using a water
jacket to avoid hypothermia. MRI data were collected using
a 1.5-T Signa scanner (General Electric Medical Systems,
Milwaukee, WI). After obtaining a fast-spoiled gradient-
echo localizer sequence (repetition time TR/echo time TE:
34.0 msec/2.2 msec, 30j flip angle), multiple axial images of
bilateral tumors in each animal were obtained (2 of 17 ani-
mals developed single tumors). All MRI acquisitions included
a conventional gradient-echo sequence: TR/TE: 3000/20,
90j flip angle, and a matrix (frequency phase = 256 128).
The field-of-view was set at 6  6 cm, and the section
thickness was 1.5 mm. All animals were imaged before and
after an intravenous injection of 5 mg/kg monocrystalline iron
oxide (MION-46L; Center for Molecular Imaging Research,
Charlestown, MA) in 100 ml of phosphate-buffered saline. The
hydrodynamic diameter of the size of these particles was
27.5 ± 6.8 nm; blood half-life was 11 hours in mice [26].
Steady-state tumoral blood volume maps were calculated
from the precontrast and postcontrast monocrystalline iron
oxide nanoparticle (MION)–enhanced MR images [24]. We
assumed that the change in the transverse relaxation rate
(DR2*) relative to the preinjection baseline relaxation rate
was proportional to the perfused local blood volume per unit
tumor volume (BV) multiplied by a function of the plasma
concentration of the agent (C): DR2* = kf(C)BV.
Assuming that the MION distribution remains constant
(steady-state distribution in blood) during the time of
MRI experiment, the equation was simplified to a linear
relationship between DR2* and the perfused blood volume
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fraction: DR2* = k VBV or BV = DR2* / k V, where DR2* is
the change in the transverse relaxation rate of the tumor
and BV is the tumor blood volume. The constant k V = 4/
3pcDvB0 includes susceptibility change Dv. The latter is
blood pool agent concentration–dependent and, therefore,
is dose-dependent.
Further, the change of relaxivity could be calculated as
DR2* = [(1/T2* post)  (1/T2* pre)] = (1/TE)[ln(Spost/Spre)],
where Spost and Spre are MR signal intensities after and
before MION administration, respectively (TE, echo time;
T2*, transverse relaxation time). The maps depicting the
change in transverse relaxation rate were calculated by
using the CMIR-Image IDL-based software (courtesy of Dr.
Ed Graves; Center for Molecular Imaging Research). On
average, seven to nine MRI slices per tumor per animal were
used in calculations (i.e., 14–18 measurements per animal
were made due to bilateral tumors). Relative vascular vol-
ume fractions (rVVFs) were obtained by scaling measure-
ments to a skeletal muscle with a known VVF of 1.9% [27].
Obtained data were analyzed by determining statistics
per tumor and per group (by analyzing combined data
obtained in each measured tumor slice; n = 66 per group).
For statistical analysis of significance between obtained
mean values, both rigorous (Student’s t test) and less
rigorous nonparametric (Mann–Whitney U test) tests gave
comparable results.
Histology
Three randomly chosen animals from each group were
injected with fluorescent labeled tomato (Lycopersicon
esculentum) lectin approximately 10 minutes before the
euthanasia. The above lectin specifically binds to fucose
residues on the surface of mouse endothelial cells [17].
Three to five midline sections and two sections obtained
from tumor edges (total: 5–7 sections per tumor, 10–14
sections per animal, and 30–36 sections per group) were
stained for apoptotic cells and images were analyzed using
fluorescence microscopy in two channels that enabled si-
multaneous analysis of vascular density, morphology, and
occurrence of apoptotic tumor cells. Tissue collection and
analysis were performed as in Ref. [25] with modifications:
Alexa Fluor 488–labeled tomato lectin (50–80 mg per animal
in 100 ml of saline) was injected 15 minutes before eutha-
nasia (n = 2 in each group, four mice in total, eight tumor
samples); tumors were excised immediately after the eutha-
nasia, frozen in liquid nitrogen, and cut into 8-mm sections
around the center (equatorial) part and the edges (10 sec-
tions per tumor sample). To determine DNA fragmenta-
tion in apoptotic cells, we used terminal deoxynucleotidyl
transferase-mediated dUTP-biotin end labeling (TUNEL)
assay (ApopTag kit; Chemicon, Temecula, CA) in combina-
tion with a Cy3-labeled antidigoxigenin F(ab V)2 fragment
(Roche Diagnostics). Fluorescence was observed and
recorded in two channels using a Zeiss Axiovert TV100
microscope equipped with a CoolSnap HQ CCD camera
(Photometrics, Tucson, AZ). Color coding and fusion of two
fluorescence channels were achieved by using the IPLab
Spectrum software (Scanalytics, Inc., Fairfax, VA).
Results
Blood Volume Measurements in Tumors
The accuracy of the DR2*-based method of rVVF mea-
surements depends on contrast agent distribution in vivo.
The hydrodynamic diameter of MION particles is in the
range of 20 to 30 nm [28], and their blood half-life is dose-
dependent and species-dependent [24,26,29]. Thus, we
initially determined whether the contrast agent (iron oxide
nanoparticles) was restricted to MV522 tumor vascular com-
partment after systemic administration. Because the total
time required for the MRI study did not exceed 1 hour, we
tested whether iron oxide showed any extravasation into
the tumor interstitium at the above time point. We addressed
this question by using the histology of tumor tissue samples
obtained from animals injected intravenously with 5 mg/ml
iron oxide (MION) and euthanized approximately 1 hour
postinjection (i.e., at a time point corresponding to the end of
the MRI experiment). The histology of frozen tumor tissue
sections stained with Prussian blue for iron and counter-
stained with eosin showed highly iron-positive blood vessels
(Figure 1A). The study revealed no detectable iron staining
outside the vessels within or outside the tumor boundaries.
The initial histologic validation of MION in the MV522
human carcinoma model was followed by a MION-assisted
T2-weighted MRI of bilateral flank tumors (Figure 1, B and C)
performed in animals that were treated either with a placebo
(Figure 1B) or with an inhibitor of VEGF type 2 receptor
kinase (Figure 1C), in three doses within 36 hours in each
group. Tumor volumes measured using calipers were 148 ±
36 mm3 (n = 16) in the placebo group vs 191 ± 38 mm3
(n = 16) in the VEGFR tyrosinase kinase inhibitor (TKI)–
treated group. The differences between tumor volumes in
these groups were statistically insignificant (P = .48). The
use of bilateral tumors allowed imaging of two tumors at
the same time in the same tomographic slice. This was
feasible because MV522 did not show any substantial
suppression of a contralateral tumor growth as only 2 of
17 mice developed a single tumor instead of two contrala-
teral tumors. The following assumptions were made to
calculate the blood volume: 1) under identical imaging con-
ditions, the blood volume of the nearby skeletal muscle
was steady; and 2) at the dose used in the study, MION in-
jection resulted in image darkening (signal loss), which was
proportional to the regional vascular volume. Sixteen-bit
grey-scale tumor region-of-interest areas were then con-
verted into pseudo-colored rVVF maps (Figure 1, B and C,
color-coded scale) using skeletal muscle signal intensity as
an intrinsic standard corresponding to 1.9% blood volume
(VVF). The resultant assessment of the average rVVF
values determined in the experimental group (n = 8 animals)
and in the control group (n = 9 animals) showed that, on the
average, rVVF was more than three times lower in animals
treated with VEGFR2-TKI tumor than in the control group
(Table 1). The differences in measured rVVF were highly
significant (Figure 2, Table 1): in the VEGFR-TKI treatment
group, rVVF was in the range of 0.95 ± 0.24% (mean ± SEM,
n = 66 slices, eight mice) compared to the untreated group
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(2.91 ± 0.24%; mean ± SEM, n = 66 slices, nine mice). By
performing a t-test of the means, assuming unequal variances
within the groups or by using a nonparametric test, we ob-
tained similar P factor values (P < .0001), suggesting a high
statistical significance of differences between the mean mea-
sured rVVF values. In a separate experiment, mice were
treated with VEGFR-TKI for a period of 6 days. In these ani-
mals, caliper-measured tumor volumeswere three times lower
in AG013925-treated groups (tumor volume 286 ± 69 mm3)
than in control animals (tumor volume 753 ± 151 mm3). The
above differences were statistically significant (P = .03).
Correlative Histology
Histology of frozen sections was performed to estab-
lish the number and morphology of perfused tumor blood
vessels, as well as the number of apoptotic TUNEL-positive
Figure 1. Iron oxide–mediated imaging of relative tumor blood volume frac-
tions in MV522 human drug-resistant colon carcinoma. (A) Prussian blue
staining of iron oxides in tumor blood vessels (counterstaining with eosin) at
1 hour postinjection. Bar = 250 m. (B) Representative images of a VEGFR-
TKI– treated mouse. On the left are shown precontrast images, postcontrast
images, and a relaxivity change (DR2*) map. On the precontrast image, an ROI
is used to measure muscle signal intensities (shown in orange); tumor ROIs
are shown in red. On the right, four consecutiveMRI sliceswith overlain pseudo-
color rVVF maps of bilateral MV522 xenografts are shown. (C) Representative
images of placebo-treated mouse. On the left are shown precontrast images,
postcontrast images, and a relaxivity change (DR2*) map. On the right are
shown four consecutive MRI slices with overlain pseudo-color rVVF maps of
bilateral MV522 xenografts. Color-coded rVVF scales are shown on the left.
Table 1. Relative Blood Volume Fraction Measurements in MV522











Per Group [% (n)]
Placebo 1 2.60 ± 0.51 8 2.91 ± 0.24 (66)**
2.94 ± 1.01
2 1.48 ± 0.33 10
2.33 ± 0.21
3 0.99 ± 0.67 4
1.82 ± 0.00
4 5.18 ± 2.83 7
2.29 ± 0.42
5 4.39 ± 2.77 5
NA
6 5.09 ± 3.98 10
3.83 ± 2.17
7 2.19 ± 0.25 6
NA
8 2.09 ± 0.33 8
1.87 ± 0.22
9 2.69 ± 1.01 8
2.86 ± 0.26
Experiment 1 1.66 ± 0.18 8 0.95 ± 0.24 (66)**
1.41 ± 0.28
2 0.67 ± 0.32 10
0.82 ± 0.24
3 0.76 ± 0.14 8
0.44 ± 0.25
4 1.05 ± 0.41 6
0.31 ± 0.09
5 1.60 ± 0.42 8
0.87 ± 0.60
6 0.34 ± 0.15 8
0.74 ± 0.22
7 0.78 ± 0.27 10
1.01 ± 0.34
8 1.52 ± 0.47 8
1.18 ± 0.39
*rVVF values measured in two bilateral tumors are shown. Not applicable
(NA) indicates that only one tumor was present in a given animal. n = total
number of slices per group used to calculate mean rVVF ± SEM per group.
**P < .0001 (Mann–Whitney nonparametric U test).
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cells. Imaging of tumor sections under blue excitation light
showed markedly dilated blood vessels in control tumors
(Figure 3A). Illumination under green excitation light re-
vealed a relatively low frequency of Cy3 (TUNEL)-positive
cells within the same sections (i.e., 6 ± 2 positive cells/mm2
section, on average). Overall, after the treatment, we ob-
served an increase of the above number to 20 ± 4 cell/mm2
(P < .05). TUNEL-positive cells were unevenly distributed
throughout tumor sections and were frequently assembled in
clusters. In addition, in treated tumor sections, histology
revealed an overall three-fold decrease of blood vessel
densities from 60 ± 20 to 21 ± 8 vessels/mm2). Remarkably,
lectin-positive vessels showed a drastic decrease in diame-
ter and no longer appeared dilated (Figure 3C). In CMC
placebo group, vascular diameter was in the range of 20 to
90 mm. After the treatment, the median diameter of tumor
vessels did not exceed 20 mm. Standard hematoxylin–eosin
stain also revealed the presence of cell death in treated
tumors that had characteristic clusters of condensed nuclei
(cf. Figure 3, D [shown with arrowheads] and B).
Discussion
Recent advances in iron oxide–mediated MRI staging of
lymph nodes in cancer patients [30], as well as novel areas
of iron oxide use in vascular and interventional radiology
[31,32], accentuated the long-standing interest in this class
of MR contrast agents. One of the potential applications of
iron oxides in the clinical setting includes the measurement
of blood volume fractions. The sensitivity of T2-type agents
to subtle changes in blood volume makes them invaluable
for assessing blood volume dynamics as a result of anti-
angiogenic treatments of cancer. The advantage of T2-type
MIONs is in their negligible extravasation into the tumor
interstitium during a typical MRI study (i.e., 45–60 minutes
[24]; Figure 1A). In contrast, low-molecular-mass chelated
gadolinium easily permeates through the leaky tumor vascu-
lar endothelium [33]. Rapid extravasation of contrast agents
may present a problem for accurate measurements of VVFs
in tumors [34]. Low-molecular-weight gadolinium-based
agents enable measurements of vascular permeability
changes (i.e., permeability–surface area product reflecting
a decrease of vascular ‘‘leak’’), which serve as an alternative
to blood volume in many MRI studies of angiogenesis [35].
However, the above compound parameter depends on a
vascular area that usually decreases as a result of vascular
diameter change and vascular disintegration induced by the
therapy [14,36], thereby introducing potential ambiguities
when treated and nontreated tumors are compared. There-
fore, in characterizing antiangiogenic therapies, blood volume
MRI measurements with iron oxides, or, alternatively, T1
macromolecular agents [34,37–40] appear more suitable.
In the current study, we performed MION-mediated MR
assessment of VVF changes in tumors treated with an
experimental antiangiogenic drug that blocks signal trans-
duction through a VEGFR2 receptor kinase. A potent and
selective small molecule VEGF/PDGF RTK inhibitor,
AG013925, demonstrated antiangiogenesis, antivascular
permeability, and antitumor efficacy in preclinical studies.
The compound dose dependently (25–100 mg/kg) induced
tumor stasis in many tumor types, including syngeneic Lewis
lung carcinoma and xenogeneic human drug-resistant
MV522 carcinoma, in mice [41,42]. At the dose of 25 mg/kg,
p.o., twice daily, the concentration of the drug in the plasma
Figure 2. The distribution of relative VVF values measured in each of the
tumoral MRI tomographic slices in VEGFR-TKI– treated and placebo-treated
groups. Mean ± SD is plotted for each group (total: 66 measurements per
group). Skeletal muscle rVVF values are shown for comparison.
Figure 3. Correlative histology of MV522 frozen sections. VEGFR2 kinase
inhibitor – treated tumors (panels A and B); control tumors (panels C and D).
(A and C) Fluorescence histology showing Alexa Fluor 488–positive tumor
blood vessels (green) and TUNEL-positive cells (red). (B and D) Hematox-
ylin –eosin–stained sections. Bar = 100 m.
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of mice surpassed the IC50 value required to stop VEGF-
mediated proliferation of endothelial cells [41]. Thus, the
above concentration was deemed sufficient to induce potent
antiangiogenic effects in mice.
A combination of a steady-state phase MRI and the ultra-
long blood half-life of MION in rodents [22] (682 ± 34 minutes
in mice [26]) enabled us to perform a quantitative analysis of
vascular volume changes occurring at a very early stage of
antiangiogenic treatment. Whereas tumor volumes mea-
sured after three doses of the VEGR-TKI were similar in
the experimental and control groups, a drastic change of
tumor vascular signal in response to the treatment was
apparent by visual examination of MR images. The signal
change translated into a three-fold drug-mediated decrease
of rVVF. The above highly significant changes observed in
treated groups of animals were confirmed by fluorescence
histology showing a narrowing of lectin-perfused tumor blood
vessels—a typical effect induced by various antiangiogenic
drugs [43] with a moderate concomitant increase of TUNEL-
positive (apoptotic) cell frequency. As demonstrated by
continuing treatments for six more days, apoptosis in tumors
of animals treated with the VEGFR-TKI becomes more
prevalent and results in tumor growth inhibition. It remains
to be determined whether reinjections of MION in the same
animal would be useful for tracking blood volume changes in
tumors over time. First, due to prolonged circulation in the
blood and relatively slow biodegradation [29], and due to a
high tumor vascular permeability, MION particles extrava-
sate into the tumor interstitium 12 to 24 hours postinjection.
Iron oxides do not extravasate into the normal muscle.
Therefore, the accuracy of relative blood volume measure-
ments could be low if performed several hours after intra-
venous administration. Second, rat tumor models should be
used with caution because dextran-coated iron oxides could
cause anaphylactoid responses [44,45]. Thus, as a general
rule, tumor blood volume MRI measurements with dextran-
coated iron oxides should be carefully timed and are most
suitable for single (early assessment) or dual time point
studies (i.e., early and late time points) due to the long
half-life in the bloodstream.
In conclusion, the results of our study suggest that iron
oxides at relatively low doses serve as excellent tracers of
perfused vascular volume in human carcinoma xenografts in
mice. We demonstrated that MION-assisted MRI could
enable the monitoring of early tumor blood volume
responses to therapy with VEGF receptor kinase inhibitors
with a potential inclusion of other antiangiogenic drugs and
translational studies.
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